Skip to main content
Top
Published in: International Urology and Nephrology 2/2014

01-02-2014 | Urology - Original Paper

Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder

Authors: Long-wang Wang, Xiao-min Han, Chao-hui Chen, Yan Ma, Bo Hai

Published in: International Urology and Nephrology | Issue 2/2014

Login to get access

Abstract

Purpose

To investigate the diagnostic performance of urinary brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) as potential biomarkers for overactive bladder (OAB).

Methods

Ninety women diagnosed with OAB and 45 normal controls without OAB were enrolled. Urine samples were collected from all subjects. Urinary BDNF and NGF levels were measured using enzyme-linked immunosorbent assays. Results normalized by urinary creatinine (Cr) levels were compared between OAB groups and controls. Symptom severity was assessed using overactive bladder symptom score.

Results

Urinary BDNF and NGF levels were elevated in OAB groups but not in controls. Mean (SD) baseline BDNF and NGF levels normalized by Cr levels were significantly higher in OAB subjects than in controls (20.609 ± 23.932 vs. 1.779 ± 0.729, p < 0.01) and (0.258 ± 0.264 vs. 0.081 ± 0.028, p < 0.01), respectively. Urinary BDNF/Cr levels were 80-fold higher than NGF/Cr levels in OAB subjects. Receiver operating characteristic curves for assessing urinary BDNF/Cr levels in OAB groups showed sensitivity and specificity of 93.33 and 88.89 %, respectively. Urinary BDNF levels were associated with OAB symptom severity.

Conclusions

Urinary BDNF/Cr levels are elevated in women with OAB and are significantly associated with symptom severity. No elevation of BDNF is found in women without OAB. BDNF analysis has better sensitivity than NGF in detecting OAB in subjects without other lower urinary tract disorders. Results of the present study suggest a potential role for BDNF as an objective biomarker for OAB diagnosis.
Literature
1.
go back to reference Milsom I, Kaplan SA, Coyne KS et al (2012) Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80:90PubMedCrossRef Milsom I, Kaplan SA, Coyne KS et al (2012) Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80:90PubMedCrossRef
2.
go back to reference Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327PubMed Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327PubMed
3.
go back to reference Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167PubMedCrossRef Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167PubMedCrossRef
5.
go back to reference Rovner ES, Goudelocke CM (2010) Urodynamics in the evaluation of overactive bladder. Curr Urol Rep 11:343PubMedCrossRef Rovner ES, Goudelocke CM (2010) Urodynamics in the evaluation of overactive bladder. Curr Urol Rep 11:343PubMedCrossRef
6.
go back to reference Steers WD, Tuttle JB (2006) Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 3:101PubMedCrossRef Steers WD, Tuttle JB (2006) Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 3:101PubMedCrossRef
7.
go back to reference Ochodnicky P, Cruz CD, Yoshimura N et al (2011) Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 30:1227PubMed Ochodnicky P, Cruz CD, Yoshimura N et al (2011) Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 30:1227PubMed
8.
go back to reference Kuo HC, Liu HT, Chancellor MB (2010) Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol 12:e69PubMedCentralPubMed Kuo HC, Liu HT, Chancellor MB (2010) Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol 12:e69PubMedCentralPubMed
9.
go back to reference Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179:2270PubMedCrossRef Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179:2270PubMedCrossRef
10.
go back to reference Antunes-Lopes T, Carvalho-Barros S, Cruz CD et al (2011) Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol 2011, Article ID 382431 Antunes-Lopes T, Carvalho-Barros S, Cruz CD et al (2011) Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol 2011, Article ID 382431
11.
go back to reference Antunes-Lopes T, Pinto R, Carvalho-Barros S et al (2011) Urinary levels of brain-derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur Urol Suppl 10:277CrossRef Antunes-Lopes T, Pinto R, Carvalho-Barros S et al (2011) Urinary levels of brain-derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur Urol Suppl 10:277CrossRef
12.
go back to reference Kuo HC, Liu HT, Chancellor MB (2010) Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 29:482PubMed Kuo HC, Liu HT, Chancellor MB (2010) Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 29:482PubMed
13.
go back to reference Kim JC, Park EY, Seo SI et al (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175: 1773; discussion 1776 Kim JC, Park EY, Seo SI et al (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175: 1773; discussion 1776
14.
go back to reference Kim JC, Park EY, Hong SH et al (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 12:875PubMedCrossRef Kim JC, Park EY, Hong SH et al (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 12:875PubMedCrossRef
15.
go back to reference Liu HT, Tyagi P, Chancellor MB et al (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681PubMedCrossRef Liu HT, Tyagi P, Chancellor MB et al (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681PubMedCrossRef
16.
go back to reference Ghoniem G, Faruqui N, Elmissary M et al (2011) Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J 22:953PubMedCrossRef Ghoniem G, Faruqui N, Elmissary M et al (2011) Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J 22:953PubMedCrossRef
17.
go back to reference Bhide AA, Cartwright R, Khullar V et al (2013) Biomarkers in overactive bladder. Int Urogynecol J 12 Jan (Epub ahead of print.) Bhide AA, Cartwright R, Khullar V et al (2013) Biomarkers in overactive bladder. Int Urogynecol J 12 Jan (Epub ahead of print.)
18.
go back to reference Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68:318PubMedCrossRef Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68:318PubMedCrossRef
19.
go back to reference Liu HT, Tyagi P, Chancellor MB et al (2009) Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 104:1476PubMedCrossRef Liu HT, Tyagi P, Chancellor MB et al (2009) Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 104:1476PubMedCrossRef
20.
go back to reference Florkowski CM (2008) Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Lin Biochem Rev 29(Suppl 1):S83 Florkowski CM (2008) Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Lin Biochem Rev 29(Suppl 1):S83
21.
go back to reference Mandrekar JN (2010) Receiver operating characteristics curve in diagnostic test assessment. J Thorac Oncol 5:1315PubMedCrossRef Mandrekar JN (2010) Receiver operating characteristics curve in diagnostic test assessment. J Thorac Oncol 5:1315PubMedCrossRef
22.
go back to reference Liu HT, Kuo HC (2008) Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 72: 104; discussion 108 Liu HT, Kuo HC (2008) Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 72: 104; discussion 108
23.
go back to reference Liu HT, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56:700PubMedCrossRef Liu HT, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56:700PubMedCrossRef
25.
go back to reference Oddiah D, Anand P, McMahon SB et al (1998) Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. NeuroReport 9:1455PubMedCrossRef Oddiah D, Anand P, McMahon SB et al (1998) Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. NeuroReport 9:1455PubMedCrossRef
26.
go back to reference Di Luca M, Gardoni F, Finardi A et al (2001) NMDA receptor subunits are phosphorylated by activation of neurotrophin receptors in PSD of rat spinal cord. NeuroReport 12:1301PubMedCrossRef Di Luca M, Gardoni F, Finardi A et al (2001) NMDA receptor subunits are phosphorylated by activation of neurotrophin receptors in PSD of rat spinal cord. NeuroReport 12:1301PubMedCrossRef
27.
go back to reference Cruz Duarte P, St-Jacques B, Ma W (2012) Prostaglandin E2 contributes to the synthesis of brain-derived neurotrophic factor in primary sensory neurons in ganglion explant cultures and in a neuropathic pain model. Exp Neurol 234:466PubMedCrossRef Cruz Duarte P, St-Jacques B, Ma W (2012) Prostaglandin E2 contributes to the synthesis of brain-derived neurotrophic factor in primary sensory neurons in ganglion explant cultures and in a neuropathic pain model. Exp Neurol 234:466PubMedCrossRef
28.
go back to reference Pezet S, McMahon SB (2006) Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29:507PubMedCrossRef Pezet S, McMahon SB (2006) Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 29:507PubMedCrossRef
29.
go back to reference Qiao LY, Vizzard MA (2002) Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways. J Comp Neurol 454:200PubMedCrossRef Qiao LY, Vizzard MA (2002) Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways. J Comp Neurol 454:200PubMedCrossRef
30.
go back to reference Qiao LY, Vizzard MA (2005) Spinal cord injury-induced expression of TrkA, TrkB, phosphorylated CREB, and c-Jun in rat lumbosacral dorsal root ganglia. J Comp Neurol 482:142PubMedCrossRef Qiao LY, Vizzard MA (2005) Spinal cord injury-induced expression of TrkA, TrkB, phosphorylated CREB, and c-Jun in rat lumbosacral dorsal root ganglia. J Comp Neurol 482:142PubMedCrossRef
31.
go back to reference Pinto R, Frias B, Allen S, Dawbarn D et al (2010) Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 166:907PubMedCrossRef Pinto R, Frias B, Allen S, Dawbarn D et al (2010) Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 166:907PubMedCrossRef
32.
go back to reference Pinto R, Lopes T, Frias B et al (2010) Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 58:360PubMedCrossRef Pinto R, Lopes T, Frias B et al (2010) Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 58:360PubMedCrossRef
Metadata
Title
Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder
Authors
Long-wang Wang
Xiao-min Han
Chao-hui Chen
Yan Ma
Bo Hai
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0540-x

Other articles of this Issue 2/2014

International Urology and Nephrology 2/2014 Go to the issue